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Aim: Cerebral malaria (CM), unlike severe malarial anemia (SMA), has previously been 
characterized by pan-lymphopenia that normalizes in convalescence, while HIV infection is 
associated with depletion of CD4+ T cells. In this study, we investigate whether HIV infection 
in Malawian children exacerbates the pan-lymphopenia associated with CM.
Methods: We investigated the absolute and percentage lymphocyte-subset counts and their 
activation and memory status in Malawian children presenting with either CM who were 
HIV-uninfected (n=29), HIV-infected (n=9), or SMA who were HIV-uninfected (n=30) and 
HIV-infected (n=5) in comparison with HIV-uninfected children without malaria (n=42) and 
HIV-infected children without malaria (n=4).
Results: HIV-infected CM cases had significantly lower absolute counts of T cells (P=0.006), 
CD4+ T cells (P=0.0008), and B cells (P=0.0014) than HIV-uninfected CM cases, and significantly 
lower percentages of CD4+ T cells than HIV-uninfected CM cases (P=0.005). HIV-infected SMA 
cases had significantly lower percentages of CD4+ T cells (P=0.001) and higher CD8+ T cells 
(P=0.003) in comparison with HIV-uninfected SMA cases. HIV-infected SMA cases had higher 
proportions of activated T cells (P=0.003) expressing CD69 than HIV-uninfected SMA cases.
Conclusion: HIV infection compounds the perturbation of acute CM and SMA on lympho-
cytes, exacerbating subset-specific lymphopenia in CM and increasing activation status in SMA, 
potentially exacerbating host immunocompromise.
Keywords: HIV, cerebral malaria, severe malarial anemia, Malawian children
Introduction
Annually, over a billion people are at risk of contracting malaria worldwide, with as 
many as 212 million clinical episodes of malaria reported in 2016, leading to 445,000 
deaths, the majority of which were among African children presenting with Plasmodium 
falciparum malaria.1 Clinical P. falciparum malaria presents either as uncomplicated 
malaria or as a severe form of the disease with cerebral malaria (CM), severe malarial 
anemia (SMA), metabolic acidosis, respiratory distress, or other complications, 
including some overlap syndromes.1,2 Of these syndromes, CM, respiratory distress, 
and SMA are associated with high mortality,1 with as many as one in seven affected 
children dying from CM or SMA in sub-Saharan Africa (SSA).3
Immunity to malaria is both humoral and cell-mediated and involves various 
mechanisms.4 Antibodies that develop through exposure to P. falciparum have a pro-
tective role,4 and the involvement of different lymphocyte subsets has been implicated 
in both protection against and pathogenesis of malaria.5–7 Cytokines, both pro- and 
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anti-inflammatory, also contributes toward parasite control 
and the pathogenesis of malaria.8,9
We and others have demonstrated that the two main 
forms of severe malaria, CM and SMA, occur in children 
with differing, though overlapping, age distributions, with 
CM typically afflicting older children.7,10 In addition, we and 
other investigators have shown that CM in HIV-uninfected 
children is characterized by transient pan-lymphopenia that 
normalizes during convalescence.7,11,12 We have further shown 
that SMA in HIV-uninfected Malawian children is character-
ized by higher lymphocyte-subset counts on average than in 
healthy controls.7
Some areas in SSA with intense malaria transmission 
also have high HIV prevalence, and so there is a likelihood 
of frequent HIV and malaria coinfection.13,14 HIV-infected 
adults tend to have higher parasite prevalence and more 
malaria episodes (risk being inversely correlated with CD4+ 
T-cell count)15 than HIV-uninfected individuals, and the HIV-
infected take longer to clear their parasitemia16 and are more 
often hospitalized due to malaria.17 HIV-infected pregnant 
Malawian women have four times the circulating malaria-
parasite loads than HIV-uninfected pregnant women, with 
high parasitemia correlating with high viral loads.18
Studies have investigated how HIV infection and P. falci-
parum malaria interact and contribute synergistically in their 
effect on the immune system in adults residing in SSA,19 but 
few investigators have examined the effect of such coinfection 
in children.20,21 Considering HIV infection is associated with a 
reduction in CD4+ T cells and CM is associated with a reduc-
tion in lymphocyte subsets,8,22 elevated lymphocyte-activation 
status, and significantly higher levels of lymphocyte-memory 
phenotype,7 we investigated the effect of HIV infection on the 
characteristics of different lymphocyte subsets in Malawian 
children presenting with CM and SMA.
Methods
Study area and population
The data presented in this paper were extracted from a 
study that was aimed at characterizing the immune cells of 
HIV-uninfected Malawian children presenting with different 
clinical types of malaria. Demographics, clinical features, 
and immunophenotyping data of these HIV-uninfected par-
ticipants have been reported previously.7,9 However, during 
recruitment, 18 (nine presenting with CM, five with SMA, 
and four without malaria) of the 188 children who consented 
to participate in the study were found to be infected with HIV. 
This paper reports analyses made between HIV-infected CM 
and SMA cases with the HIV-uninfected CM and SMA cases.
The study was hosted at the Malawi Liverpool Wellcome 
Trust Clinical Research Programme, with some of the inves-
tigators based in the Department of Pediatrics, College of 
Medicine, University of Malawi and others in the Blantyre 
Malaria Project. The study cases were children who were 
admitted to Queen Elizabeth Central Hospital with acute 
malaria of different clinical types. The controls were medi-
cally well children attending surgical outpatient clinics at 
Queen Elizabeth Central Hospital and Beit Cure International 
Hospital, both in Blantyre, Malawi.
All study participants were enrolled during the malaria 
season (November 2005 to April 2006), which coincides with 
the rainy season, after obtaining informed consent from the 
parent or guardian. Each participant was initially examined 
by a research nurse and clinical officer, who then collected 
baseline demographic data and drew a venous blood sample for 
analysis. Criteria defining clinical malaria were fever, a clinical 
syndrome compatible with malaria without any apparent alter-
native cause, and a thick blood film positive for P. falciparum 
asexual parasites on microscopy. Those participants presenting 
with malaria were assessed for level of consciousness using 
the Blantyre coma score on admission and at 2- to 4-hourly 
intervals during intensive clinical care. Overall, over 40 chil-
dren were enrolled presenting with CM and a similar number 
prospectively enrolled presenting with SMA. Those presenting 
with CM had a Blantyre coma score of ≤2 at the time of being 
admitted into the study and at 4 hours after admission and a 
hemoglobin concentration >5 g/dL at both stages. In contrast, 
study participants presenting with SMA had a blood hemoglo-
bin concentration of ≤5 g/dL and a Blantyre coma score of 5. 
Children who presented with symptoms characteristic of both 
CM and SMA were excluded from the final data analysis. All 
children were tested for their HIV status, and those found to be 
infected were placed in either the CM-HIV coinfected group 
or the SMA-HIV coinfected group. Study participants who 
presented with SMA in the absence of any other complications 
were treated with a standard regimen of sulfadoxine–pyrimeth-
amine, which was the first-line treatment for malaria in Malawi 
at the time. In contrast, those children who fitted the criteria 
for CM were treated with intramuscular quinine, which was 
also the recommended treatment against CM in Malawi at that 
time. Children who were HIV-uninfected and free of malaria 
and those who were HIV-infected but not infected with malaria 
were also recruited in the study as control participants.
Malaria microscopy
As is standard procedure, thick and thin films were prepared 
for determining malaria parasitemia, with the thin films also 
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used in examination to confirm the species of the infecting 
Plasmodium parasite. Preparation and reading of malaria 
slides were performed in accordance with standard World 
Health Organization procedures,23 and two blood slides were 
prepared from each participant’s blood sample. Each slide 
had a measured volume of 6 µL blood for thick film and 2 
µL for the thin film stained with Giemsa.
HIV testing
HIV tests were done using EDTA-anticoagulated blood on 
the same day venous blood samples were collected. The 
tests were done using two rapid tests: Determine (Abbott 
Laboratories, Abbott Park, IL, USA) and Uni-Gold (Trinity 
Biotech, Dublin, Ireland). In the event that discordant results 
were obtained for one sample and also where a sample tested 
positive for children aged >18 months, the results were con-
firmed or discredited using a PCR method that has previously 
been reported.24
Full blood count and immunophenotyping
Part of the EDTA-anticoagulated blood sample was used for 
performing a full blood count using an HMX hematological 
analyzer (Beckman Coulter, Brea, CA, USA) and an aliquot 
was used for the immunophenotyping analyses. Immunophe-
notyping involved labeling 25 µL blood samples with various 
monoclonal antibodies, as specified in Table S1. All antibod-
ies (Table S2) were sourced from BD Biosciences (San Jose, 
CA, USA). The labeled samples were processed and data 
acquired using a FACSCalibur flow cytometer and CellQuest 
software (BD Biosciences) as previously described.7,25
Statistical analysis
For statistical analysis, study participants were divided into 
six groups: those who were HIV-infected but without malaria, 
those who were HIV-uninfected and without malaria, those 
who were HIV-infected and presented with CM, those who 
were HIV-uninfected and presented with CM, those who 
were HIV-infected and presented with SMA, and those who 
were HIV-uninfected and presented with SMA. For statisti-
cal analyses based on clinical type of malaria, four groups 
were analyzed together at a time such that the groups of 
HIV-infected non-malaria (first comparator), HIV-uninfected 
non-malaria (second comparator), HIV-infected CM, and 
HIV-uninfected CM were analyzed together and the results 
are presented in Table 1. Similarly, the four groups – HIV-
infected non-malaria (first comparator), HIV-uninfected 
non-malaria (second comparator), HIV-infected SMA, 
and HIV-uninfected SMA – were analyzed together, and 
the results are presented in Table 2. Medians and ranges 
(25th and 75th percentiles) were calculated for absolute and 
percentage leukocyte- and lymphocyte-subset proportions, 
activation, and memory status of different cells in each group 
(Tables 1 and 2 and Figures 1 and 2). The Kruskal–Wallis 
equality-of-population rank test was used to identify overall 
differences among the four groups (groups 1–4) for each cell 
type. Subsequently, Dunn’s test was used to pinpoint which 
specific medians were significantly different from the others. 
Both the Kruskal–Wallis test and Dunn’s test were performed 
in R-version 3.3.1 using the Dunn test package. Pairwise 
differences between two groups were then determined using 
the two-sample Wilcoxon rank-sum (Mann–Whitney) test. 
P≤0.0125 was considered statistically significant at a 95% 
level of confidence. All figures were produced using Graph-
Pad Prism.
Ethical approval
The study protocol was reviewed and approved by the College 
of Medicine Research and Ethics Committee, University of 
Malawi, and the Ethics Committee of the Liverpool School of 
Tropical Medicine, UK. Either the parent or guardian of each 
study participant provided informed written consent on their 
behalf for the child to be included in the study. This study was 
conducted in accordance with the Declaration of Helsinki.
Results
Characteristics of study participants
Among the 38 children presenting with CM, nine (24%) were 
HIV-infected, and of the 35 presenting with SMA, five (14%) 
were HIV-infected. Of the nine HIV-infected CM children, 
the median age was 48 (14–55) months and five (56%) were 
male. Of the five HIV-infected SMA cases, the median age 
was 19 (6–28) months and two (40%) were male. For the 29 
HIV-uninfected CM cases, the median age was 30 (5–84) 
months and ten (34%) were male.7 For the 30 HIV-uninfected 
SMA cases, the median age was 23 (5–38) months and 19 
(63%) were male.7 Among the HIV-uninfected non-malaria 
controls (n=42), 29 (69%) were male and the median age 
was 20 (5–76) months.7 For the HIV-infected non-malaria 
controls (n=4), two (50%) were male and the median age 
was 19 (3–53) months.
HIV infection exacerbates perturbation 
of lymphocyte-subset cell counts by 
association with CM
Platelet and white blood-cell counts were similar in HIV-
infected and in HIV-uninfected children presenting with 
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Mandala et al
Figure 1 Median values (plotted on a log scale).
Notes: Platelet counts (A), leukocyte counts (B), percentage (C), and absolute counts (D) of different lymphocyte subsets, percentages of T, NK, and γδ T lymphocytes 
expressing activation markers CD69 and HLA-DR (E) and memory CD4+ and CD8+ shown by expression of CD45RO and memory B cells by expression of CD27 (F) in 
peripheral blood at acute presentation in Malawian children either coinfected with HIV and cerebral malaria (red dots) or with cerebral malaria only (black dots).
Abbreviations: B, B cells; gdT, gamma/delta T cells; M, memory cells; NK, Natural killer cells; T, T cells; WBCs, white blood cells.
H
IV
+  
pl
at
el
et
s
10
100
10,000 100
100 100
10
1
0.1
10
1
0.1
0.01
10
1
100P=0.002
P=0.05
10
1
P=0.01 P<0.01 P<0.01
1,000
100
10
1
1,000
H
IV
–  p
la
te
le
ts
H
IV
+  
W
BC
s
H
IV
–  W
BC
s
H
IV
+  
ne
ut
ro
ph
ils
H
IV
–  n
eu
tro
ph
ils
H
IV
+  
ly
m
ph
oc
yt
es
H
IV
–  l
ym
ph
oc
yt
es
H
IV
+  T
H
IV
–  T
H
IV
+  
C
D
4+
 T
H
IV
–  C
D
4+
 T
H
IV
+  
C
D
8+
 T
H
IV
–  C
D
8+
 T
H
IV
+  
B 
ce
lls
H
IV
–  B
 c
el
ls
H
IV
+  
N
K
H
IV
–  N
K
H
IV
+  
gd
T
H
IV
–  g
dT
H
IV
+  T
H
IV
–  T
H
IV
+  
C
D
4+
 T
H
IV
–  C
D
4+
 T
H
IV
+  
C
D
8+
 T
H
IV
–  C
D
8+
 T
H
IV
+  
B 
ce
lls
H
IV
–  B
 c
el
ls
H
IV
+  
N
K
H
IV
–  N
K
H
IV
+  
gd
T
H
IV
–  g
dT
%
 a
ct
iv
at
ed
 c
el
ls
Ly
m
ph
oc
yt
e 
su
bs
et
 c
ou
nt
s
Pl
at
el
et
 c
ou
nt
s 
(×
10
3 )
/µ
l
Le
uc
oc
yt
e 
co
un
ts
 (×
10
9 /L
)
%
 ly
m
ph
oc
yt
e 
su
bs
et
s
%
 m
em
or
y 
ce
lls
H
IV
+  
C
D
69
+T
H
IV
–  C
D
69
+T
H
IV
+  
C
D
69
+g
dT
H
IV
–  C
D
69
+g
dT
H
IV
+  
C
D
69
+N
K
H
IV
–  C
D
69
+N
K
H
IV
+  
D
R
+N
K
H
IV
–  D
R
+N
K
H
IV
+  
D
R
+g
dT
H
IV
–  D
R
+g
dT
H
IV
+  
M
+C
D
4
H
IV
–  M
+C
D
4
H
IV
+  
M
+C
D
8+
H
IV
–  M
+C
D
8
H
IV
+  
M
+B
H
IV
–  M
+B
H
IV
+  
m
on
oc
yt
es
H
IV
–  m
on
oc
yt
es
A B C
D E F
Figure 2 Median values (plotted on a log scale).
Notes: Platelet counts (A), leukocyte counts (B), percentage (C), and absolute counts (D) of different lymphocyte subsets, percentages of T, NK, and γδ T lymphocytes 
expressing activation markers CD69 and HLA-DR (E) and memory CD4+ and CD8+ shown by expression of CD45RO and memory B cells expressed by CDD27 (F) in 
peripheral blood at acute presentation in Malawian children either coinfected with HIV and severe malarial anemia (red dots) or with severe malarial malaria only (black dots).
Abbreviations: B, B cells; gdT, gamma/delta T cells; M, memory cells; NK, Natural killer cells; T, T cells; WBCs, white blood cells.
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CM (Figure 1, A and B, Table 1). Similarly, neutrophil, 
lymphocyte, and monocyte counts did not differ signifi-
cantly between HIV-infected and HIV-uninfected CM cases 
(Figure 1B). However, children presenting with CM (both 
HIV-infected and HIV-uninfected) had significantly lower 
platelet, neutrophil, lymphocyte, and monocyte counts 
than in the HIV-infected or HIV-uninfected group without 
malaria (Table 1). HIV-infected CM cases had significantly 
lower median percentage CD4+ T cells (as percentage of 
total lymphocytes) compared than HIV-uninfected CM cases 
(P=0.005; Figure 1C, Table 1). Furthermore, HIV-infected 
CM cases had significantly lower absolute counts of total 
T cells (P=0.006), CD4+ T cells (P=0.0008), and B cells 
(P=0.001) than counts in HIV-uninfected CM cases (Figure 
1D, Table 1).
HIV infection contributes to level of 
activation but not memory status 
associated with CM
The activation status of T (CD3+), NK (CD56+), and γδ T 
(TCRγδ+) cells, either by expression of the marker CD69 
(early activation) or HLA-DR (late activation), was measured 
for all groups. HIV-uninfected CM cases had significantly 
(P<0.0001) higher proportions of CD69+ T, CD69+ NK and 
CD69+ γδ T cells than the HIV-uninfected non-malaria group 
(Table 1). HIV-infected CM cases had significantly higher 
percentages of activated γδ T cells by expression of HLA-DR 
(P=0.002) than HIV-uninfected CM cases (Figure 1E, Table 
1). However, HIV-infected CM cases (35.3%) had similar pro-
portions of HLA-DR+ γδ T cells to those of the HIV-infected 
non-malaria group (32.9%), while HIV-uninfected CM cases 
(16.4%) had significantly (P=0.004) lower proportions of 
HLA-DR+ γδ T cells than the HIV-uninfected non-malaria 
group (26.85%). HIV-uninfected CM cases (45.10%) had a 
significantly (P<0.0001) higher percentage of memory CD4+ 
T cells than HIV-uninfected non-malaria cases (26.84%; 
Figure 1F, Table 1).
HIV infection is associated with reduction 
in specific blood-cell counts in SMA cases 
compared to HIV-uninfected SMA cases
Platelet counts were low in children presenting with SMA 
(but only significantly so for the HIV-uninfected groups) 
than non-malaria controls, regardless of their HIV status 
(P<0.01 for the HIV-uninfected groups), but leukocytes 
were lower only in HIV-uninfected CM cases than controls 
(Figure 2, A and B, Table 2). HIV-infected SMA cases had a 
significantly lower percentage of CD4+ T cells (P=0.001) than 
HIV-uninfected SMA cases (Figure 2C, Table 2), but similar 
absolute counts of different lymphocyte subsets (Figure 2D).
HIV-infected SMA cases have on average 
higher lymphocyte activation and 
memory status than HIV-uninfected 
children with SMA
Just as was the case with CM cases, we measured the activa-
tion status, as expressed by both CD69 and HLA-DR, of T, 
NK, and γδ T cells. Firstly, HIV-uninfected SMA cases had 
significantly higher proportions of CD69+ T cells (28.46% 
vs 21.08%, P=0.009), CD69+ NK cells (49.43% vs 25.77%, 
P<0.0001), and CD69+ γδ T cells (51.94% vs 23.83%, 
P<0.0001) than HIV-uninfected non-malaria cases, sug-
gesting a link between SMA and the activation status of 
these lymphocyte subsets independently of HIV infection. 
Secondly, we found that HIV-infected SMA cases had a 
significantly (P=0.0032) higher proportion of CD69+ T cells 
(54.7%) than HIV-uninfected SMA cases (28.5%), suggest-
ing that HIV infection may increase activation caused by 
SMA. In addition, HIV-uninfected SMA cases had signifi-
cantly (P=0.003) higher proportions of activated γδ T cells 
expressed by HLA-DR than HIV-uninfected non-malaria 
cases (Figure 2E, Table 2).
HIV-infected SMA cases had a significantly higher propor-
tion of memory CD8+ T cells (45.9% vs 14.4%, P=0.0004) 
than HIV-uninfected SMA cases. In addition, HIV-infected 
non-malaria cases had a significantly (P=0.0022) higher pro-
portion of memory CD8+ T cells (37.9% vs 16.4%) than HIV-
uninfected non-malaria cases, suggesting that this difference 
could be due to the HIV infection alone (Figure 2F, Table 2).
CM cases had higher parasitemia levels 
than SMA cases
HIV-uninfected CM cases (66,286 parasites/µL) had sig-
nificantly (P=0.0043) higher levels of parasitemia than 
HIV-uninfected SMA cases (13,446 parasites/µL). There 
was no statistical difference between the parasitemia levels 
of HIV-infected and -uninfected CM cases or HIV-infected 
and -uninfected SMA cases.
Discussion
Malaria and HIV, both separately and together, are still con-
tributing significantly to the high morbidity and mortality 
in SSA.20 Although various studies have looked at either the 
effect of malaria on HIV or the effect of HIV on malaria, very 
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few studies have looked at how cell-mediated immunity is 
affected in children coinfected with HIV and CM21 or SMA. 
In this study, we found that the reduction in percentages of 
CD4+ T-cell, B-cell, and γδ T-cell lymphocytes and increase 
in activation status of lymphocyte subsets previously reported 
among HIV-uninfected children presenting with CM7 were 
compounded in those coinfected with CM and HIV. We also 
found lower absolute counts of CD4+ T cells, B cells, and 
NK cells in HIV-infected than HIV non-infected children 
presenting with CM. The study also showed that both HIV-
infected CM and SMA cases were characterized by higher 
levels of activation and memory status than HIV-uninfected 
CM and SMA cases. Although HIV-infected children who did 
not present with malaria had reduced CD4+ T cells compared 
to HIV-uninfected controls, as is expected for HIV-infected 
subjects, coinfection of HIV with CM resulted in a further 
reduction in absolute counts of this T-cell subset, suggest-
ing that CM may compound the HIV-related loss of CD4+ T 
cells from peripheral blood. Due to the smaller samples of 
the HIV-infected CM and SMA cases compared to the HIV-
uninfected groups, some differences described (particularly 
where P-values approached 0.0125, the cutoff for signifi-
cance) might not be biologically important.
The HIV-related but malaria-independent activation 
expressed by the marker CD69 observed in this study has 
been reported before,26 although the combined effect of HIV 
and malaria infections on cell-activation status has not been 
reported extensively. We have previously shown that acute 
malaria, regardless of clinical type, was associated with 
increased proportions of lymphocytes expressing the marker 
CD69, with γδ T and NK cells showing a more prominent 
increase.7 A similar outcome was also observed in this study, 
where all malaria cases, regardless of HIV status, had higher 
proportions of CD69+ T, NK, and γδ T cells.
This study had several limitations. Firstly, the samples 
of the HIV-infected children, both with CM (n=9) and SMA 
(n=5), were small compared to the HIV-uninfected partici-
pants (n=29 for CM and n=30 for SMA). Furthermore, all 
14 HIV-infected participants recruited in this study were 
not aware whether they were infected with HIV or not at 
the time of recruitment, and as such they were not on highly 
active antiretroviral therapy (HAART). Immediately after 
being diagnosed with HIV, they were referred to a HAART 
clinic to commence treatment. Being HAART-naïve, viral 
load measurements would have provided further useful data 
 concerning clinical status. With larger samples, compari-
sons could have been more meaningful if stratified by CD4 
count and/or viral load. Since we had previously shown 
that CM-related pan-lymphopenia normalizes 30 days into 
convalescence in HIV-uninfected children,7 it would be inter-
esting to know whether the same occurs in CM cases who 
are HIV-infected. Unfortunately, there were only two study 
participants in this group who returned during convalescence, 
and thus statistical analysis was not possible.
Conclusion
We have shown that HIV infection compounds the lympho-
penia observed in CM in African children and increases 
activation of lymphocyte subsets in those with acute SMA. In 
light of widespread prevention of mother-to-child transmis-
sion (the Option B+ initiative) among HIV-infected pregnant 
women, future longitudinal studies should concentrate on 
investigating further how P. falciparum-specific immunity 
is affected in HIV-exposed uninfected children residing in 
malaria-endemic areas.
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Supplementary materials
Table S1 Monoclonal antibodies used and corresponding cell populations
FITC PE PerCP APC Identity of subsets
moGI moGI moGI moGI Isotype control
N/A CD27 N/A CD19 Memory/naïve B cells
HLA-DR CD56 CD3 CD69 T cells, Natural killer cells, Natural 
Killer T cells cell-activation status
TCRγ/δ HLA-DR N/A CD69 γδ+ T cells, activation status
N/A CD4 CD3 CD8 CD4+ and CD8+ T cells
CD45RA CD45RO CD4 CD8 Memory/naïve CD4+ and CD8+ T cells
N/A N/A N/A N/A Negative control
Abbreviations: APC, allophycocyanin; FITC, fluorescein isothiocyanate; NA, not applicable; PE, phycoerythrin; PerCP, peridinin chlorophyll protein; T, T cells; NK = 
Natural Killer Cells; NKT = Natural Killer T cells.
Table S2 Monoclonal antibodies and names of suppliers
Monoclonal antibody Product number Supplier
Anti-CD3-PerCP 560835 BD
Anti-CD4-FITC 555346 BD
Anti-CD8-APC 561952 BD
Anti-CD19-APC 641395 BD
Anti-CD25-APC 560987 BD
Anti-CD27-PE 340425 BD
Anti-CD28-FITC 555728 BD
Anti-CD38-APC 560239 BD
Anti-CD45-PerCP 555483 BD
Anti-CD45RA-FITC 555488 BD
Anti-CD45RO-PE 555493 BD
Anti-CD56-PE 555516 BD
Anti-CD57-FITC 555619 BD
Anti-CD69-APC 555533 BD
Anti-HLA-DR-FITC 555560 BD
Anti-HLA-DR-PE 555812 BD
Anti-TCR-γ/δ-FITC 347903 BD
Anti-TCR-Vδ2-PE 555739 BD
Anti-moGI-FITC 555909 BD
Anti-moGI-PE 555749 BD
Anti-moGI-PerCP 555751 BD
Anti-moGI-APC 550795 BD
Abbreviations: APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, 
phycoerythrin; PerCP, peridinin chlorophyll protein.
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